GENE ONLINE|News &
Opinion
Blog

2025-11-28|

Mixed Fermentation with Saccharomyces cerevisiae and Lactobacillus Species Reduces Sugar Content and Enhances Flavor in Pumpkin Juice

by GOAI
Share To

A recent study examined the impact of mixed fermentation involving *Saccharomyces cerevisiae*, *Lactobacillus helveticus*, and *Lactobacillus delbrueckii subsp. bulgaricus* on the physicochemical properties and flavor profile of pumpkin juice. Researchers analyzed how this combination of microorganisms influenced factors such as acidity, sugar content, volatile compounds, and overall sensory characteristics of the juice.

The findings revealed that the mixed fermentation process significantly altered the chemical composition of pumpkin juice. The pH levels decreased due to increased lactic acid production, while sugar content was reduced as a result of microbial metabolism. Additionally, the fermentation process enhanced the formation of volatile compounds associated with improved flavor profiles, including esters and alcohols. Sensory analysis indicated that these changes contributed to a more favorable taste perception among participants. The study highlights how specific microbial combinations can modify both nutritional and sensory attributes in plant-based beverages like pumpkin juice.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 28, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top